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Background: The aim of this thesis was to become more familiar with the issue of renal 
cancer, treatment options, focusing on targeted therapy and its specific products, comparing 
results from registration studies and RENIS database and evaluating results of targeted 
therapy in clinical practice. 
Main findings: The main treatment for localized kidney cancer is surgical removal of the 
tumour. Targeted biological treatment, which focuses only on tumor cells, becomes more 
used in treatment of advanced and metastatic stages. Currently are registered tyrosine-
kinase inhibitors of receptors for angiogenic growth factors, sorafenib, sunitinib, axitinib and 
pazopanib, monoclonal antibody neutralizing vascular endothelial growth factor 
bevacizumab and mTOR inhibitors and everolimus, temsirolimus. 
Conclusions: The results of targeted therapies in clinical practice in the Czech Republic are 
comparable with the results of registered randomized trials, and in some cases are even 
better. Targeted therapy is a revolutionary change in the treatment of RCC. It prolongs most 
patients’ lives, extends time to disease progression, improves patients’ quality of life, but still 
mRCC remains an incurable disease. 
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